KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $4.8 million.

  • Alnylam Pharmaceuticals' Current Deferred Revenue fell 9126.73% to $4.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.8 million, marking a year-over-year decrease of 9126.73%. This contributed to the annual value of $4.8 million for FY2025, which is 9126.73% down from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Current Deferred Revenue is $4.8 million, which was down 9126.73% from $2.5 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Current Deferred Revenue high stood at $290.8 million for Q4 2023, and its period low was $2.5 million during Q3 2025.
  • Its 5-year average for Current Deferred Revenue is $94.3 million, with a median of $77.0 million in 2023.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Current Deferred Revenue soared by 11470.08% in 2024 and then tumbled by 9642.26% in 2025.
  • Alnylam Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $149.5 million in 2021, then surged by 57.56% to $235.5 million in 2022, then grew by 23.45% to $290.8 million in 2023, then crashed by 80.92% to $55.5 million in 2024, then plummeted by 91.27% to $4.8 million in 2025.
  • Its Current Deferred Revenue was $4.8 million in Q4 2025, compared to $2.5 million in Q3 2025 and $15.1 million in Q2 2025.